Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Palifermin
A Menarini Australia Pty Ltd
Medicine Registered
KEPIVANCE ® 1 KEPIVANCE ® _PALIFERMIN (RBE) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about KEPIVANCE. It does not contain all the available information. It does not take the place of talking to your doctor or nurse. This leaflet was last updated on the date at the end of this leaflet. SPEAK TO YOUR DOCTOR OR NURSE TO OBTAIN THE MOST UP TO DATE INFORMATION ON THIS MEDICINE. You can also download the most up to date leaflet from www.menarini.com.au. All medicines have risks and benefits. Your doctor has weighed the risks of you having KEPIVANCE against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR NURSE. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT KEPIVANCE IS USED FOR Kepivance is used to reduce a condition called oral mucositis in patients with cancers of the blood receiving certain types of chemotherapy and/or radiotherapy. Oral mucositis is inflammation and ulceration of the lining of the mouth and throat. Kepivance is a man-made form of a naturally-occurring substance called Keratinocyte Growth Factor, sometimes shortened to KGF. Keratinocyte Growth Factor stimulates the growth of epithelial cells which are the uppermost layer of cells that line your mouth, digestive tract and skin. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is available only with a doctor's prescription. BEFORE YOU ARE GIVEN KEPIVANCE _WHEN YOU MUST NOT BE GIVEN _ _IT _ DO NOT HAVE KEPIVANCE IF YOU HAVE AN ALLERGY TO: any medicine containing palifermin. any of the ingredients listed at the Read the complete document
KEPI-V08 Page 1 of 10 KEPIVANCE (PALIFERMIN) NAME OF THE MEDICINE Palifermin is a human keratinocyte growth factor (KGF) produced by recombinant DNA technology in _Escherichia coli_. Kepivance is the Swedish Orphan Biovitrum AB (publ) trademark for palifermin (rbe). DESCRIPTION Palifermin is a water-soluble 140 amino acid protein with a molecular weight of 16.3 kilodaltons. It differs from endogenous human KGF in that the first 23 N-terminal amino acids have been deleted to improve protein stability. Kepivance is a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as an intravenous (IV) injection. Each single-use vial of Kepivance contains 6.25 mg palifermin, 50 mg mannitol, 25 mg sucrose, 1.94 mg L-histidine and 0.13 mg polysorbate 20. Vials of Kepivance are reconstituted with 1.2 mL of sterile Water for Injections to yield a palifermin concentration of 5 mg/mL. Reconstitution yields a clear, colourless solution of Kepivance with a pH of 6.5. PHARMACOLOGY PHARMACODYNAMICS Keratinocyte growth factor (KGF) is an endogenous protein in the fibroblast growth factor (FGF) family that binds to the KGF receptor. Binding of KGF to its receptor has been reported to result in proliferation, differentiation and migration of epithelial cells. The KGF receptor, one of four receptors in the FGF family, has been reported to be present on epithelial cells in many tissues examined including the tongue, buccal mucosa, oesophagus, stomach, intestine, sa Read the complete document